Home > Press > Arrowhead Research to Present at BIO-Europe 2012
Abstract:
Arrowhead Research Corporation (NASDAQ: ARWR), a targeted therapeutics company, today announced that Dr. Chris Anzalone, President and Chief Executive Officer, will present a corporate overview at the 18th annual BIO-Europe international partnering conference on Tuesday November 13th at 3:30 pm in Hamburg, Germany.
Arrowhead Research to Present at BIO-Europe 2012
Pasadena, CA | Posted on November 12th, 2012
BIO-Europe is the preeminent partnering conference serving the global biotechnology industry, with this year's event drawing 3,000 industry attendees from over 30 countries, representing close to 1,800 companies.
####
About Arrowhead Research Corporation
Arrowhead Research Corporation is a clinical stage targeted therapeutics company with development programs in oncology, obesity, and chronic hepatitis B virus infection. The company is leveraging its platform technologies to design and develop peptide-drug conjugates (PDCs) that specifically home to cell types of interest while sparing off-target tissues, create targeted drugs based on the gene silencing RNA interference (RNAi) mechanism, and work with partners to create improved versions of traditional small molecule drugs.
For more information please visit www.arrowheadresearch.com, or follow us on Twitter @ArrowRes. To be added to the Company's email list to receive news directly, please send an email to
For more information, please click here
Contacts:
Arrowhead Research
Vince Anzalone
CFA
626-304-3400
The Trout Group, LLC
Lauren Glaser
646-378-2972
Copyright © Arrowhead Research Corporation
If you have a comment, please
Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Bookmark:
News and information
Aspen Aerogels Announces $22.5 Million Private Placement May 18th, 2013
NanoInk, Inc. Assets To Be Sold May 18th, 2013
Beautiful "flowers" self-assemble in a beaker: Elaborate nanostructures blossom from a chemical reaction perfected at Harvard May 17th, 2013
Scientists capture first direct proof of Hofstadter butterfly effect May 17th, 2013
Nanomedicine
Nanotechnology could help fight diabetes: Injectable nanogel can monitor blood-sugar levels and secrete insulin when needed May 16th, 2013
Nanobiotix Revenue for the 1st quarter of 2013 May 15th, 2013
Pitt Chemists Demonstrate Nanoscale Alloys So Bright They Could Have Potential Medical Applications: “Think about a particle that will not only help researchers detect cancer sooner but be used to treat the tumor, too.” May 15th, 2013
Using clay to grow bone: Researchers use synthetic silicate to stimulate stem cells into bone cells May 15th, 2013
Announcements
Aspen Aerogels Announces $22.5 Million Private Placement May 18th, 2013
NanoInk, Inc. Assets To Be Sold May 18th, 2013
NIA Public Briefing: Nanotechnology and the Council of Europe May 17th, 2013
Scientists capture first direct proof of Hofstadter butterfly effect May 17th, 2013
Events/Classes
Interactive Printed Products – New Applications Enabled by Organic and Printed Electronics May 16th, 2013
Nanometrics Announces Upcoming Investor Events May 14th, 2013
INSCX™ exchange to present a nanotechnology-based Emission Reduction Programme, Ankara, Turkey, June 2013 May 14th, 2013
VDMA: New “Photonics Industry Report 2013” presented May 14th, 2013